cox 189 has been researched along with indomethacin in 12 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (indomethacin) | Trials (indomethacin) | Recent Studies (post-2010) (indomethacin) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 29,527 | 1,838 | 3,396 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blobaum, AL; Marnett, LJ | 2 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE | 1 |
| Birkenmeier, K; Felix, SB; Janke, I; Krieg, T; Labitzke, C; Landsberger, M; Prange, T; Schunck, WH; Stangl, V; Staudt, A; Trimpert, C | 1 |
| Campos, ML; Chelucci, R; Chiquetto, R; Chung, MC; dos Santos, JL; Peccinini, RG | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
3 review(s) available for cox 189 and indomethacin
| Article | Year |
|---|---|
Structural and functional basis of cyclooxygenase inhibition.
Topics: Animals; Cardiovascular System; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Kinetics; Models, Molecular; Protein Conformation; Risk Assessment | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
1 trial(s) available for cox 189 and indomethacin
| Article | Year |
|---|---|
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Topics: Abdominal Pain; Acute Disease; Administration, Oral; Adult; Aged; Analysis of Variance; Argentina; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Germany; Gout; Headache; Humans; Indomethacin; Joints; Logistic Models; Male; Middle Aged; Pain Measurement; Treatment Outcome; Vertigo | 2007 |
8 other study(ies) available for cox 189 and indomethacin
| Article | Year |
|---|---|
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
Topics: Amino Acid Substitution; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Kinetics; Male; Membrane Proteins; Mice; Models, Molecular; Mutation, Missense; Protein Binding; Protein Structure, Tertiary; Sheep; Time Factors | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia.
Topics: Adenosine Triphosphate; Animals; Calcium Signaling; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Depression, Chemical; Diastole; Diclofenac; Disease Models, Animal; Glyburide; In Vitro Techniques; Indomethacin; Myocardial Contraction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Nitrobenzenes; Perfusion; Potassium Channel Blockers; Potassium Channels; Rats; Reperfusion Injury; Research Design; Sulfonamides; Systole; Time Factors | 2007 |
Synthesis, characterization and pharmacological evaluation of 1-(2-chloro-6-fluorophenyl)-5-methylindolin-2-one: a new anti-inflammatory compound with reduced gastric ulceration properties.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Movement; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Stability; Female; Gastric Mucosa; Hydrogen-Ion Concentration; Indoles; Indomethacin; Lactams; Male; Mice; Prodrugs; Rats; Rats, Wistar; Stomach Ulcer | 2010 |